Clopidogrel Bisulfate

14,533 adverse event reports submitted to the FDA (2004–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Clopidogrel Bisulfate in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Clopidogrel Bisulfate adverse event reports by reporter sex
SexReports
Male7,936
Female5,379
Unknown37

By Age Group

View age group data as a table
Clopidogrel Bisulfate adverse event reports by reporter age group
Age groupReports
0-1771
18-3474
35-49557
50-642,620
65-743,542
75+4,393

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Clopidogrel Bisulfate. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Clopidogrel Bisulfate adverse event reports by reported outcome
OutcomeReports
Other Serious7,836
Hospitalization7,262
Non-Serious1,772
Death1,667
Life-Threatening1,201
Disability461

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Clopidogrel Bisulfate. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Clopidogrel Bisulfate adverse event reports by year
YearReports
2004670
2005899
2006324
2007213
2008178
2009242
2010341
2011253
2012342
2013332
2014528
2015434
2016623
2017766
20181,062
20191,060
2020880
2021970
20221,147
20231,074
2024998
20251,007
2026 (partial)190

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Clopidogrel Bisulfate

In FDA adverse event reports that mention Clopidogrel Bisulfate, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026